Clinical Study

A Phase 1/?2 Study Of Mrtx0902 In Solid Tumors With Mutations In The Kras Mapk Pathway

Posted Date: Apr 26, 2024

  • Investigator: Davendra Sohal
  • Specialties: Cancer, Colorectal Cancer, Lung Cancer
  • Type of Study: Drug

This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.

Criteria:

Null

Keywords:

Advanced Solid Tumor, Non Small Cell Lung Cancer

For More Information:

Kayla Webb
NULL
cancer@uchealth.com